You are viewing the site in preview mode
Skip to main content
| Factors | Number (%) | HR (95% CI) | P value |
|---|
| Age |
| < 60 years | 162 (46.29) | Reference | |
| ≥ 60 years | 188 (53.71) | 0.98 (0.97, 1.00) | 0.0297 |
| Sex |
| Male | 254 (72.57) | Reference | |
| Female | 96 (27.43) | 0.88 (0.62, 1.26) | 0.4927 |
| KPS |
| 70–80 | 242 (69.14) | Reference | |
| 90–100 | 108 (30.86) | 1.00 (0.98, 1.03) | 0.7220 |
| Primary Site |
| Rectum | 266 (76.00) | Reference | |
| Rectosigmoid | 84 (24.00) | 1.12(0.53,1.18) | 0.6210 |
| T Stage |
| T2 | 24 (6.86) | Reference | |
| T3 | 176 (50.29) | 2.86 (1.05, 7.83) | 0.0406 |
| T4 | 150 (42.86) | 3.16 (1.15, 8.64) | 0.0253 |
| N Stage |
| N0 | 50 (14.29) | Reference | |
| N1 | 114 (32.57) | 0.88 (0.44, 1.75) | 0.7192 |
| N2 | 86 (24.57) | 2.03 (1.05, 3.93) | 0.0350 |
| N+ | 86 (24.57) | 4.09 (2.21, 7.59) | < 0.0001 |
| Nx | 14 (4.00) | 7.01 (3.14, 15.66) | < 0.0001 |
| M Stage |
| M1a | 180 (51.43) | Reference | |
| M1b | 146 (41.71) | 1.09 (0.77, 1.54) | 0.6163 |
| M1c | 24 (6.86) | 2.39 (1.46, 3.91) | 0.0006 |
| Differentiation |
| Well | 28 (8.00) | Reference | |
| Moderate | 198 (56.57) | 0.28 (0.17, 0.47) | < 0.0001 |
| Poor | 110 (31.43) | 1.00 (0.61, 1.65) | 0.9877 |
| Unknown | 14 (4.00) | 0.95 (0.22, 4.07) | 0.9444 |
| Chemotherapy Cycles |
| 4–8 | 247(70.57) | Reference | |
| 9–12 | 103(29.43) | 0.79 (0.69, 0.90) | 0.0002 |
| Second-line Chemotherapy |
| No | 276 (78.86) | Reference | |
| Yes | 74 (21.14) | 0.37 (0.22, 0.63) | 0.0002 |
| Chemotherapy Response |
| Poor | 146 (41.71) | Reference | |
| Good | 204 (58.29) | 0.82 (0.59, 1.13) | 0.0217 |
| Metastatic Tumor radiotherapy |
| Yes | 180 (51.43) | Reference | |
| No | 170 (48.57) | 1.53 (1.11, 2.11) | 0.0102 |
| Primary Tumor Radiotherapy |
| No | 187 (53.43) | Reference | |
| Yes | 163 (46.57) | 0.39 (0.28, 0.56) | < 0.0001 |
